Dopamine D1 receptors are involved in the modulation of D2 receptors induced by cholecystokinin receptor subtypes in rat neostriatal membranes

[1]  K. Fuxe,et al.  Cholecystokinin Octapeptide In Vitro and Ex Vivo Strongly Modulates Striatal Dopamine D2 Receptors in Rat Forebrain Sections , 1995, The European journal of neuroscience.

[2]  D. Surmeier,et al.  Are neostriatal dopamine receptors co-localized? , 1993, Trends in Neurosciences.

[3]  K. Fuxe,et al.  The C-terminal neurotensin-(8-13) fragment potently modulates rat neostriatal dopamine D2 receptors. , 1993, European journal of pharmacology.

[4]  K. Fuxe,et al.  Neurotensin and cholecystokinin octapeptide control synergistically dopamine release and dopamine D2 receptor affinity in rat neostriatum. , 1993, European journal of pharmacology.

[5]  H. Akil,et al.  Comparison of the distributions of D1 and D2 dopamine receptor mRNAs in rat brain. , 1991, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.

[6]  G. Euler.  Biochemical characterization of the intramembrane interaction between neurotensin and dopamine D2 receptors in the rat brain , 1991, Brain Research.

[7]  B. Costall,et al.  Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[8]  S. Cooper,et al.  SCH 23390-Induced hypophagia is blocked by the selective CCK-A receptor antagonist devazepide, but not by the CCK-B/gastrin receptor antagonist L-365,260 , 1990, Brain Research Bulletin.

[9]  G. Woodruff,et al.  Autoradiographical detection of cholecystokinin-A receptors in primate brain using 125I-Bolton Hunter CCK-8 and 3H-MK-329 , 1990, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[10]  C. Altar.  Cholecystokinin receptor subtypes and neuromodulation , 1989, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[11]  P. Seeman,et al.  Link between D1 and D2 dopamine receptors is reduced in schizophrenia and Huntington diseased brain. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[12]  H J Motulsky,et al.  Fitting curves to data using nonlinear regression: a practical and nonmathematical review , 1987, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[13]  T. Moroji,et al.  A comparative study on characterization and distribution of cholecystokinin binding sites among the rat, mouse and guinea pig brain , 1986, Brain Research.

[14]  R. Chang,et al.  Biochemical and pharmacological characterization of an extremely potent and selective nonpeptide cholecystokinin antagonist. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[15]  S. Lal,et al.  Cholecystokinin peptides, dopamine and schizophrenia — A review , 1985, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[16]  G A McPherson,et al.  Analysis of radioligand binding experiments. A collection of computer programs for the IBM PC. , 1985, Journal of pharmacological methods.

[17]  K. Fuxe,et al.  Cholecystokinin Neuron Systems and Their Interactions with the Presynaptic Features of the Dopamine Neuron Systems , 1985, Annals of the New York Academy of Sciences.

[18]  J. Crawley.  Cholecystokinin Potentiation of Dopamine‐mediated Behaviors in the Nucleus Accumbens , 1985, Annals of the New York Academy of Sciences.

[19]  K. Fuxe,et al.  Evidence for Cholecystokinin‐Dopamine Receptor Interactions in the Central Nervous System of the Adult and Old Rat , 1985, Annals of the New York Academy of Sciences.

[20]  S O Ogren,et al.  Specific in vitro and in vivo binding of 3H-raclopride. A potent substituted benzamide drug with high affinity for dopamine D-2 receptors in the rat brain. , 1985, Biochemical pharmacology.

[21]  G. Zetler.  Neuropharmacological Profile of Cholecystokinin‐like Peptides , 1985, Annals of the New York Academy of Sciences.

[22]  C. Marsden,et al.  SCH 23390 may alter dopamine-mediated motor behaviour via striatal D-1 receptors. , 1985, Biochemical pharmacology.

[23]  J. Rehfeld.  Neuronal Cholecystokinin: One or Multiple Transmitters? , 1985, Journal of neurochemistry.

[24]  D. de Wied,et al.  In rats, the behavioral profile of CCK-8 related peptides resembles that of antipsychotic agents. , 1983, European journal of pharmacology.

[25]  J. Hyttel.  SCH 23390 - the first selective dopamine D-1 antagonist. , 1983, European journal of pharmacology.

[26]  K. Fuxe,et al.  Cholecystokinin peptides in vitro modulate the characteristics of the striatal 3H-N-propylnorapomorphine sites. , 1983, Acta physiologica Scandinavica.

[27]  T. Hökfelt,et al.  Differential modulation by CCK-8 and CCK-4 of [3H]spiperone binding sites linked to dopamine and 5-hydroxytryptamine receptors in the brain of the rat , 1983, Neuroscience Letters.

[28]  T. Hökfelt,et al.  Modulation by cholecystokinins of 3H-spiroperidol binding in rat striatum: evidence for increased affinity and reduction in the number of binding sites. , 1981, Acta physiologica Scandinavica.

[29]  T. Hökfelt,et al.  Cholecystokinin peptides produce marked reduction of dopamine turnover in discrete areas in the rat brain following intraventricular injection. , 1980, European journal of pharmacology.

[30]  T. Hökfelt,et al.  Evidence for coexistence of dopamine and CCK in meso-limbic neurones , 1980, Nature.

[31]  I. Creese,et al.  3H-N-n-propylnorapomorphine: a novel agonist ligand for central dopamine receptors. , 1979, European journal of pharmacology.

[32]  G. W. Snedecor.  STATISTICAL METHODS , 1967 .

[33]  Seymour Geisser,et al.  Statistical Principles in Experimental Design , 1963 .

[34]  Oliver H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.

[35]  P. Strange.  D1/D2 dopamine receptor interaction at the biochemical level. , 1991, Trends in pharmacological sciences.

[36]  K. Fuxe,et al.  Modulation of Dopamine D1 and D2 Transmission Lines in the Central Nervous System , 1990 .

[37]  B. Bloch,et al.  Dopamine receptor gene expression by enkephalin neurons in rat forebrain. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[38]  T. Segawa,et al.  Selective blockade of dopamine D-1 receptor by SCH 23390 affects dopamine agonist binding to 3H-spiperone labeled D-2 receptors in rat striatum. , 1989, Japanese journal of pharmacology.

[39]  F. J. White,et al.  Cholecystokinin, dopamine and schizophrenia , 1984 .